PIEZO1 mechanically regulates the antitumour cytotoxicity of T lymphocytes

Ruiyang Pang,Weihao Sun,Yingyun Yang,Dahan Wen,Feng Lin,Dingding Wang,Kailong Li,Ning Zhang,Junbo Liang,Chunyang Xiong,Yuying Liu

DOI: https://doi.org/10.1038/s41551-024-01188-5

IF: 28.1

2024-03-22

Nature Biomedical Engineering

Abstract:The killing function of cytotoxic T cells can be enhanced biochemically. Here we show that blocking the mechanical sensor PIEZO1 in T cells strengthens their traction forces and augments their cytotoxicity against tumour cells. By leveraging cytotoxic T cells collected from tumour models in mice and from patients with cancers, we show that PIEZO1 upregulates the transcriptional factor GRHL3, which in turn induces the expression of the E3 ubiquitin ligase RNF114. RNF114 binds to filamentous actin, causing its downregulation and rearrangement, which depresses traction forces in the T cells. In mice with tumours, the injection of cytotoxic T cells collected from the animals and treated with a PIEZO1 antagonist promoted their infiltration into the tumour and attenuated tumour growth. As an immunomechanical regulator, PIEZO1 could be targeted to enhance the outcomes of cancer immunotherapies.

engineering, biomedical

What problem does this paper attempt to address?

This paper aims to explore the role of the mechanosensor PIEZO1 in T lymphocytes and its impact on tumor cell killing function. Specifically, the study found that inhibiting PIEZO1 in T cells can enhance their ability to kill tumor cells. By conducting experiments with cells collected from mouse tumor models and cancer patients, researchers revealed that PIEZO1 upregulates the expression of the transcription factor GRHL3, which in turn induces the expression of the E3 ubiquitin ligase RNF114. RNF114 binds to microfilaments (F-actin), leading to their downregulation and rearrangement, thereby weakening the traction force of T cells. In mouse tumor models, injecting cells treated with a PIEZO1 antagonist can promote T cell infiltration into tumor tissues and slow down tumor growth.

Furthermore, the study proposes that PIEZO1, as a key target for mechanically regulating immune responses, may become a new avenue for improving cancer immunotherapy efficacy. By combining with immune checkpoint inhibitors (such as anti-PD-1 antibodies), the inhibition of PIEZO1 can significantly enhance therapeutic outcomes. Therefore, targeting PIEZO1 and its related mechanoregulation pathways may bring new opportunities for cancer immunotherapy.